1446358-48-0Relevant articles and documents
Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator
Rennie, Glen R.,Barden, Timothy C.,Bernier, Sylvie G.,Carvalho, Andrew,Deming, Renee,Germano, Peter,Hudson, Colleen,Im, G-Yoon J.,Iyengar, Rajesh R.,Jia, Lei,Jung, Joon,Kim, Elise,Lee, Thomas W.-H.,Mermerian, Ara,Moore, Joel,Nakai, Takashi,Perl, Nicholas R.,Tobin, Jenny,Zimmer, Daniel P.,Renhowe, Paul A.
, (2021/03/22)
Soluble guanylate cyclase (sGC) is a clinically validated therapeutic target in the treatment of pulmonary hypertension. Modulators of sGC have the potential to treat diseases that are affected by dysregulation of the NO-sGC-cGMP signal transduction pathw
SOLID DISPERSIONS COMPRISING A SGC STIMULATOR
-
Page/Page column 56-57, (2017/06/27)
The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.
SGC STIMULATORS
-
Paragraph 00295, (2016/04/20)
The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC